AAPL   382.73 (+0.36%)
MSFT   214.32 (+0.70%)
FB   244.50 (+0.38%)
GOOGL   1,518.66 (+1.00%)
AMZN   3,182.63 (+3.29%)
NVDA   420.36 (+2.87%)
CGC   16.02 (-1.90%)
BABA   261.58 (+1.51%)
MU   49.98 (+0.54%)
GE   6.58 (-4.08%)
TSLA   1,394.28 (+2.08%)
AMD   57.26 (+7.17%)
T   29.54 (-3.02%)
ACB   11.77 (-3.21%)
F   5.84 (-4.11%)
GILD   74.71 (-1.19%)
DIS   116.81 (+0.13%)
BAC   22.77 (-1.43%)
NFLX   507.76 (+0.99%)
BA   173.28 (-3.78%)
AAPL   382.73 (+0.36%)
MSFT   214.32 (+0.70%)
FB   244.50 (+0.38%)
GOOGL   1,518.66 (+1.00%)
AMZN   3,182.63 (+3.29%)
NVDA   420.36 (+2.87%)
CGC   16.02 (-1.90%)
BABA   261.58 (+1.51%)
MU   49.98 (+0.54%)
GE   6.58 (-4.08%)
TSLA   1,394.28 (+2.08%)
AMD   57.26 (+7.17%)
T   29.54 (-3.02%)
ACB   11.77 (-3.21%)
F   5.84 (-4.11%)
GILD   74.71 (-1.19%)
DIS   116.81 (+0.13%)
BAC   22.77 (-1.43%)
NFLX   507.76 (+0.99%)
BA   173.28 (-3.78%)
AAPL   382.73 (+0.36%)
MSFT   214.32 (+0.70%)
FB   244.50 (+0.38%)
GOOGL   1,518.66 (+1.00%)
AMZN   3,182.63 (+3.29%)
NVDA   420.36 (+2.87%)
CGC   16.02 (-1.90%)
BABA   261.58 (+1.51%)
MU   49.98 (+0.54%)
GE   6.58 (-4.08%)
TSLA   1,394.28 (+2.08%)
AMD   57.26 (+7.17%)
T   29.54 (-3.02%)
ACB   11.77 (-3.21%)
F   5.84 (-4.11%)
GILD   74.71 (-1.19%)
DIS   116.81 (+0.13%)
BAC   22.77 (-1.43%)
NFLX   507.76 (+0.99%)
BA   173.28 (-3.78%)
AAPL   382.73 (+0.36%)
MSFT   214.32 (+0.70%)
FB   244.50 (+0.38%)
GOOGL   1,518.66 (+1.00%)
AMZN   3,182.63 (+3.29%)
NVDA   420.36 (+2.87%)
CGC   16.02 (-1.90%)
BABA   261.58 (+1.51%)
MU   49.98 (+0.54%)
GE   6.58 (-4.08%)
TSLA   1,394.28 (+2.08%)
AMD   57.26 (+7.17%)
T   29.54 (-3.02%)
ACB   11.77 (-3.21%)
F   5.84 (-4.11%)
GILD   74.71 (-1.19%)
DIS   116.81 (+0.13%)
BAC   22.77 (-1.43%)
NFLX   507.76 (+0.99%)
BA   173.28 (-3.78%)
Log in

OTCMKTS:EKTAYELEKTA AB/ADR Stock Price, Forecast & News

$9.31
-0.27 (-2.84 %)
(As of 07/9/2020 04:00 PM ET)
Add
Compare
Today's Range
$9.31
Now: $9.31
$9.50
50-Day Range
$8.87
MA: $9.74
$10.83
52-Week Range
$6.25
Now: $9.31
$14.76
Volume3,287 shs
Average Volume12,145 shs
Market Capitalization$3.56 billion
P/E Ratio27.38
Dividend Yield1.36%
Beta0.7
Elekta AB (publ) provides equipment and software for cancer and brain disorders worldwide. The company offers radiotherapy systems under the Versa HD, Precise Treatment System, and Elekta Compact names; Elekta Infinity, an image-guided radiation therapy (IGRT) system; and Elekta Synergy, a digital accelerator for advanced IGRT. It also provides personalized imaging tools; automation and integration systems; beam shaping solutions; patient positioning and immobilization solutions; and radiotherapy treatment planning systems. In addition, the company offers radiosurgery systems under the Leksell Gamma Knife Icon, Leksell Gamma Knife Perfexion, and Elekta Axesse names; Leksell GammaPlan, a treatment planning software; and Elekta Unity, a magnetic resonance radiation therapy solution. Further, it provides care management software, such as MOSAIQ Radiation Oncology and MOSAIQ Medical Oncology; MOSAIQ IQ Scripts, a workflow automation and customization tool; Patient Engagement, a patient communication tool; MOSAIQ Evaluate, a plan management and dose review solution; MOSAIQ Locate, a stereotactic localization solution; and METRIQ, a cancer registry data management solution. Additionally, the company offers Flexitron, a remote after loading platform; microSelectron, a digital pulsed dose rate platform; Esteya, an electronic brachytherapy for treating skin cancer; Oncentra Brachy, a treatment planning software; real-time prostate solutions; and gynecological brachytherapy, bronchus and esophagus, breast, prostate, rectum and bladder, and skin applicators, as well as brachytherapy needles and flexible implant tubes. It also provides Leksell Vantage Stereotactic System for neuroimaging and treatment; Elekta Neuromag TRIUX, a magnetoencephalography system; Leksell Stereotactic System for minimally invasive stereotactic neurosurgery; and proton therapy components. The company was founded in 1972 and is headquartered in Stockholm, Sweden.
Read More
ELEKTA AB/ADR logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.2Dividend Strength: 1.7Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.02 out of 5 stars


Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:EKTAY
CUSIPN/A
CIKN/A
Phone46-8-587-254-00

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.44 billion
Cash Flow$0.59 per share
Book Value$2.26 per share

Profitability

Net Income$132.74 million

Miscellaneous

Employees3,800
Market Cap$3.56 billion
Next Earnings Date7/15/2020 (Estimated)
OptionableNot Optionable

Receive EKTAY News and Ratings via Email

Sign-up to receive the latest news and ratings for EKTAY and its competitors with MarketBeat's FREE daily newsletter.

ELEKTA AB/ADR (OTCMKTS:EKTAY) Frequently Asked Questions

How has ELEKTA AB/ADR's stock been impacted by COVID-19 (Coronavirus)?

ELEKTA AB/ADR's stock was trading at $9.29 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, EKTAY shares have increased by 0.2% and is now trading at $9.3095. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of ELEKTA AB/ADR?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ELEKTA AB/ADR in the last year. There are currently 1 sell rating and 3 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for ELEKTA AB/ADR.

When is ELEKTA AB/ADR's next earnings date?

ELEKTA AB/ADR is scheduled to release its next quarterly earnings announcement on Wednesday, July 15th 2020. View our earnings forecast for ELEKTA AB/ADR.

Has ELEKTA AB/ADR been receiving favorable news coverage?

News coverage about EKTAY stock has trended somewhat negative this week, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. ELEKTA AB/ADR earned a news sentiment score of -1.6 on InfoTrie's scale. They also gave news stories about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the next several days. View the latest news about ELEKTA AB/ADR.

Who are some of ELEKTA AB/ADR's key competitors?

Who are ELEKTA AB/ADR's key executives?

ELEKTA AB/ADR's management team includes the following people:
  • Mr. Laurent Leksell, Founder & Chairman (Age 67)
  • Dr. Richard Hausmann, Pres & CEO (Age 59)
  • Mr. Gustaf Salford, CFO & Exec. VP (Age 42)
  • Mr. Steven Wort, COO & Group VP of Manufacturing & Logistics (Age 56)
  • Mr. John Lapré, Chief Technology Officer (Age 55)

What is ELEKTA AB/ADR's stock symbol?

ELEKTA AB/ADR trades on the OTCMKTS under the ticker symbol "EKTAY."

How do I buy shares of ELEKTA AB/ADR?

Shares of EKTAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is ELEKTA AB/ADR's stock price today?

One share of EKTAY stock can currently be purchased for approximately $9.31.

How big of a company is ELEKTA AB/ADR?

ELEKTA AB/ADR has a market capitalization of $3.56 billion and generates $1.44 billion in revenue each year. The company earns $132.74 million in net income (profit) each year or $0.33 on an earnings per share basis. ELEKTA AB/ADR employs 3,800 workers across the globe.

What is ELEKTA AB/ADR's official website?

The official website for ELEKTA AB/ADR is www.elekta.com.

How can I contact ELEKTA AB/ADR?

ELEKTA AB/ADR's mailing address is P.O. Box 7593, Stockholm V7, SE-103 93. The company can be reached via phone at 46-8-587-254-00 or via email at [email protected]

This page was last updated on 7/9/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.